An interventional study of Pumpkin seed extract (Low dose) and Pumpkin seed extract (High dose) in Diabetes and Metabolic Disease, sponsored by Greenyn Biotechnology Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Greenyn Biotechnology Co., Ltd. · Not applicable, Interventional, and Prevention
This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract on blood sugar management in subhealth people.
997 studies on the registry are indexed under Metabolic Diseases; 234 are open to participants now.
This study's planned enrollment of 60 is above the median of 48 across 670 interventional studies indexed under Metabolic Diseases.
Browse Metabolic Diseases studies →Greenyn Biotechnology Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo capsule, one capsule/day (300 mg/day) for 3 months
Dietary Supplement: Placebo
Pumpkin seed extract capsule, one capsule/day (300 mg/day) for 3 months
Dietary Supplement: Pumpkin seed extract (Low dose)
Pumpkin seed extract capsule, two capsules/day (600 mg/day) for 3 months
Dietary Supplement: Pumpkin seed extract (High dose)
Pumpkin seed extract standardized with specific peptides (300 mg/day)
Pumpkin seed extract standardized with specific peptides (600 mg/day)
Placeo (300 mg/day)
Biochemical analysis
Changes in fasting blodd sugar levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Biochemical analysis
Changes in glycosylated hemoglobin levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Biochemical analysis
Changes in insulin levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Biochemical analysis
Changes in incremental area under the curve for glucose for 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Hormone analysis
Changes in GLP-1 levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Hormone analysis
Changes in DPP4 levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Hormone analysis
Changes in adiponectin levels of 60 pariticpants will be analyzed between baseline and week 12.
Time frame: Baseline up to 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Greenyn Biotechnology Co., Ltd.